Zai Lab Limited (ZLAB)
(Delayed Data from NSDQ)
$16.25 USD
-0.34 (-2.05%)
Updated May 3, 2024 04:00 PM ET
After-Market: $16.23 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.25 USD
-0.34 (-2.05%)
Updated May 3, 2024 04:00 PM ET
After-Market: $16.23 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye
5 Stocks With Recent Price Strength to Enhance Your Return
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Moving Average Crossover Alert: Zai Lab Limited
by Zacks Equity Research
Zai Lab Limited Unsponsored ADR (ZLAB) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Will Zai Lab Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Zai Lab Limited (ZLAB).
Zai Lab (ZLAB) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Zai Lab (ZLAB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails
by Zacks Equity Research
Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.